Newborn Screening for CAH-Challenges and Opportunities
Newborn screening for congenital adrenal hyperplasia (CAH) using 17-hydroxyprogesterone (17-OHP) as an indicator of disease was first introduced in the 1970s [...]
Saved in:
Main Authors: | Natasha L. Heather (Author), Anna Nordenstrom (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CAH Newborn Screening in India: Challenges and Opportunities
by: Aashima Dabas, et al.
Published: (2020) -
Measurement of 17-Hydroxyprogesterone by LCMSMS Improves Newborn Screening for CAH Due to 21-Hydroxylase Deficiency in New Zealand
by: Mark R de Hora, et al.
Published: (2020) -
Thirty-Year Lessons from the Newborn Screening for Congenital Adrenal Hyperplasia (CAH) in Japan
by: Atsumi Tsuji-Hosokawa, et al.
Published: (2021) -
Newborn Screening by Genomic Sequencing: Opportunities and Challenges
by: David Bick, et al.
Published: (2022) -
Should CAH in females be classified as DSD?
by: Ricardo eGonzález, et al.
Published: (2016)